Skip to main content
Clinical Trials/ISRCTN73579020
ISRCTN73579020
Completed
Phase 2

Randomised placebo-controlled, double-blind, exploratory trial of Bosentan for Steroid-resistant Pulmonary Sarcoidosis: the BOSSA Study

niversity Hospital Basel (Switzerland)0 sites36 target enrollmentSeptember 27, 2010

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Sarcoidosis with pulmonary involvement
Sponsor
niversity Hospital Basel (Switzerland)
Enrollment
36
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Registry
who.int
Start Date
September 27, 2010
End Date
December 31, 2012
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity Hospital Basel (Switzerland)

Eligibility Criteria

Inclusion Criteria

  • 1\. Biopsy\-proven sarcoidosis with pulmonary involvement stages II, III, (IV) according to Silzbach
  • 2\. Persistant symptoms on long\-term oral corticosteroids (greater than 2 months; 5 mg prednisone or equivalent and/or other immunosuppressive agents
  • 3\. Aged greater than 18 years
  • 4\. Informed written consent
  • 5\. Impaired exercise capacity (oxygen uptake \[VO2] peak less than 80%) or resting lung functions (forced expiratory volume in one second \[FEV1], forced vital capacity \[FVC] or diffusing capacity of the lung for carbon monoxide \[DLCO] less than 80%)

Exclusion Criteria

  • 1\. Systemic illness other than sarcoidosis requiring immunosuppressive therapy
  • 2\. Honey combing greater than 10% on High Resolution Computed Tomography \[HRCT] scan
  • 3\. Marked disturbance of liver enzymes at baseline
  • 4\. Pregnancy
  • 5\. Relevant psychiatric illness or addictive disorder
  • 6\. Previous or current treatment with bosentan
  • 7\. Therapry with cyclosporine A

Outcomes

Primary Outcomes

Not specified

Similar Trials